Email Alert RSS
Volume 14 Issue 5
Sep.  2023
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2023  >  14(5): 945-952
CHEN Yuqing, LI Jinming. Virological Characteristics of the Omicron Variant: Key Mutations, Pathogenicity, and Immune Escape[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 945-952. doi: 10.12290/xhyxzz.2023-0139
Citation: CHEN Yuqing, LI Jinming. Virological Characteristics of the Omicron Variant: Key Mutations, Pathogenicity, and Immune Escape[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 945-952. doi: 10.12290/xhyxzz.2023-0139
shu

Virological Characteristics of the Omicron Variant: Key Mutations, Pathogenicity, and Immune Escape

doi: 10.12290/xhyxzz.2023-0139
  • 1.

    National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing 100730, China

  • 2.

    National Center for Clinical Laboratories, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author: LI Jinming, E-mail: jmli@nccl.org.cn
  • Received Date: 2023-03-21
  • Accepted Date: 2023-05-05
    • Available Online: 2023-05-08
  • Publish Date: 2023-09-30
    Abstract
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant was first detected in Botswana and subsequently led to a worldwide surge in infections. Until now, Omicron and its lineages, the most highly mutated strains among variants of concern (VOC), have contained at least 50 mutations in the entire genome. Mutations give the virus certain adaptive advantages, such as the enhanced affinity between receptor binding domain (RBD) and human angiotensin-converting enzyme 2 (ACE2) receptors leading to enhanced transmission of the virus, and the weakened ability of virus replication leading to mild symptoms in patients with COVID-19. In addition, given its high environmental stability, Omicron can partially escape the host immune response induced by vaccination or prior infection, and is highly resistant tomost therapeutic antibodies.In this paper, key mutations, virological characteristics, pathogenicity, and immune escape of the Omicron variant are summarized, in order to provide scientific reference for coping with the new situation of the pandemic, as well as improving pandemic prevention and control strategy and public health measures.
    • FullText(HTML)
  • loading
    • References(61)
  • [1] World Health Organization. WHO Coronavirus (COVID-19) Dashboard With Vaccination Data[EB/OL].(2023-05-03)[2023-05-05]. https://covid19.who.int/?gclid=CjwKCAiAlNf-.
    [2] World Health Organization. Tracking SARS-CoV-2 variants[EB/OL].(2023-04-27)[2023-05-05]. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
    [3] Vaughan A. Omicron emerges[J]. New Sci, 2021, 252: 7.
    [4] Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness[J]. Nat Rev Microbiol, 2023, 21: 162-177.
    [5] Hirose R, Itoh Y, Ikegaya H, et al. Differences in environmental stability among SARS-CoV-2 variants of concern: Both Omicron BA. 1 and BA. 2 have higher stability[J]. Clin Microbiol Infect, 2022, 28: 1486-1491. doi:  10.1016/j.cmi.2022.05.020
    [6] Hu J, Peng P, Cao X, et al. Increased immune escape of the new SARS-CoV-2 variant of concern Omicron[J]. Cell Mol Immunol, 2022, 19: 293-295. doi:  10.1038/s41423-021-00836-z
    [7] Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic[J]. Lancet, 2021, 398: 2126-2128. doi:  10.1016/S0140-6736(21)02758-6
    [8] Pastorio C, Zech F, Noettger S. Determinants of spike infectivity, processing and neutralization in SARS-CoV-2 Omicron subvariants BA. 1 and BA. 2[J]. Cell Host Microbe, 2022, 30: 1255-1268. doi:  10.1016/j.chom.2022.07.006
    [9] Chen J, Qiu Y, Wang R, et al. Persistent Laplacian projected Omicron BA. 4 and BA. 5 to become new dominating variants[J]. Comput Biol Med, 2022, 151: 106262. doi:  10.1016/j.compbiomed.2022.106262
    [10] Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19[J]. Nat Rev Microbiol, 2021, 19: 141-154. doi:  10.1038/s41579-020-00459-7
    [11] Tian D, Sun Y, Xu H, et al. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant[J]. J Med Virol, 2022, 94: 2376-2383. doi:  10.1002/jmv.27643
    [12] Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B. 1.1.529 leads to widespread escape from neutralizing antibody responses[J]. Cell, 2022, 185: 467-484. e15. doi:  10.1016/j.cell.2021.12.046
    [13] Chen J, Wang R, Gilby NB, et al. Omicron variant (B. 1.1.529): infectivity, vaccine breakthrough, and antibody resistance[J]. J Chem Inf Model, 2022, 62: 412-422. doi:  10.1021/acs.jcim.1c01451
    [14] Chan YA, Zhan SH. The emergence of the spike furin cleavage site in SARS-CoV-2[J]. Mol Biol Evol, 2022, 39: msab327. doi:  10.1093/molbev/msab327
    [15] Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B. 1.1.7 and B. 1.351 variants to neutralizing antibodies[J]. Nat Med, 2021, 27: 917-924. doi:  10.1038/s41591-021-01318-5
    [16] Wang Q, Ye SB, Zhou ZJ, et al. Key mutations in the spike protein of SARS-CoV-2 affecting neutralization resistance and viral internalization[J]. J Med Virol, 2023, 95: e28407. doi:  10.1002/jmv.28407
    [17] Cox MG, Peacock TP, Harvey WT, et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies[J]. Nat Rev Microbiol, 2023, 21: 112-124. doi:  10.1038/s41579-022-00809-7
    [18] Li Q, Nie J, Wu J, et al. SARS-CoV-2 501Y. V2 variants lack higher infectivity but do have immune escape[J]. Cell, 2021, 184: 2362-2371. e9. doi:  10.1016/j.cell.2021.02.042
    [19] Yu J, Collier AY, Rowe M, et al. Neutralization of the SARS-CoV-2 Omicron BA. 1 and BA. 2 variants[J]. N Engl J Med, 2022, 386: 1579-1580. doi:  10.1056/NEJMc2201849
    [20] Rodino KG, Peaper DR, Kelly BJ, et al. Partial ORF1ab gene target failure with Omicron BA. 2.12.1[J]. J Clin Microbiol, 2022, 60: e00600-22.
    [21] Cao Y, Yisimayi A, Jian F, et al. BA. 2.12.1, BA. 4 and BA. 5 escape antibodies elicited by Omicron infection[J]. Nature, 2022, 608: 593-602. doi:  10.1038/s41586-022-04980-y
    [22] Liu C, Lu J, Li P, et al. A Comparative study on epidemiological characteristics, transmissibility, and pathogenicity of three COVID-19 outbreaks caused by different variants[J]. Int J Infect Dis, 2023. doi:  10.1016/j.ijid.2023.01.039.
    [23] Kumar S, Karuppanan K, Subramaniam G. Omicron (BA. 1) and sub-variants (BA. 1.1, BA. 2, and BA. 3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assess-ment[J]. J Med Virol, 2022, 94: 4780-4791. doi:  10.1002/jmv.27927
    [24] Fantini J, Yahi N, Colson P, et al. The puzzling mutational landscape of the SARS-CoV-2-variant Omicron[J]. J Med Virol, 2022, 94: 2019-2025. doi:  10.1002/jmv.27577
    [25] Fantini J, Yahi N, Azzaz F, et al. Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating COVID-19 outbreaks[J]. J Infect, 2021, 83: 197-206. doi:  10.1016/j.jinf.2021.06.001
    [26] Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA. 2.12.1, BA. 4 and BA. 5[J]. Nature, 2022, 608: 603-608. doi:  10.1038/s41586-022-05053-w
    [27] Benvenuto D, Angeletti S, Giovanetti M, et al. Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy[J]. J Infect, 2020, 81: e24-e27.
    [28] Goldswain H, Dong X, Penrice-Randal R, et al. The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection[J]. Genome Biol, 2023, 24: 47. doi:  10.1186/s13059-023-02881-5
    [29] Wu H, Xing N, Meng K, et al. Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2[J]. Cell Host Microbe, 2021, 29: 1788-1801. e6. doi:  10.1016/j.chom.2021.11.005
    [30] Garcia-Beltran WF, Denis KJS, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant[J]. Cell, 2022, 185: 457-466. e4. doi:  10.1016/j.cell.2021.12.033
    [31] Zhao H, Lu L, Peng Z, et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells[J]. Emerg Microbes Infect, 2022, 11: 277-283. doi:  10.1080/22221751.2021.2023329
    [32] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020, 181: 271-280. e8. doi:  10.1016/j.cell.2020.02.052
    [33] Suzuki R, Yamasoba D, Kimura I, et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant[J]. Nature, 2022, 603: 700-705. doi:  10.1038/s41586-022-04462-1
    [34] Shuai H, Chan JFW, Hu B, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B. 1.1.529 Omicron[J]. Nature, 2022, 603: 693-699. doi:  10.1038/s41586-022-04442-5
    [35] Yamasoba D, Kimura I, Nasser H, et al. Virological characteristics of the SARS-CoV-2 Omicron BA. 2 spike[J]. Cell, 2022, 185: 2103-2115. e19. doi:  10.1016/j.cell.2022.04.035
    [36] Ito K, Piantham C, Nishiura H. Estimating relative generation times and relative reproduction numbers of Omicron BA. 1 and BA. 2 with respect to Delta in Denmark[J]. Math Biosci Eng, 2022, 19: 9005-9017. doi:  10.3934/mbe.2022418
    [37] Qassim SH, Chemaitelly H, Ayoub HH, et al. Effects of BA. 1/BA. 2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections[J]. J Travel Med, 2022, 29: taac068. doi:  10.1093/jtm/taac068
    [38] Kimura I, Yamasoba D, Tamura T, et al. Virological characteristics of the SARS-CoV-2 Omicron BA. 2 subvariants, including BA. 4 and BA. 5[J]. Cell, 2022, 185: 3992-4007. e16. doi:  10.1016/j.cell.2022.09.018
    [39] Tegally H, Moir M, Everatt J, et al. Emergence of SARS-CoV-2 omicron lineages BA. 4 and BA. 5 in South Africa[J]. Nat Med, 2022, 28: 1785-1790. doi:  10.1038/s41591-022-01911-2
    [40] Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron(B. 1.1.529) and delta (B. 1.617.2) variants in England: a cohort study[J]. Lancet, 2022, 399: 1303-1312. doi:  10.1016/S0140-6736(22)00462-7
    [41] Bager P, Wohlfahrt J, Bhatt S, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study[J]. Lancet Infect Dis, 2022, 22: 967-976. doi:  10.1016/S1473-3099(22)00154-2
    [42] Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study[J]. Lancet, 2022, 399: 437-446. doi:  10.1016/S0140-6736(22)00017-4
    [43] Wang L, Berger NA, Kaelber DC, et al. Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron[J]. medRxiv[Preprint]. 2022. doi:  10.1101/2021.12.30.21268495.
    [44] Espenhain L, Funk T, Overvad M, et al. Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021[J]. Euro Surveill, 2021, 26: 2101146.
    [45] Goga A, Bekker LG, Garrett N, et al. Breakthrough SARS-CoV-2 infections during periods of delta and omicron predominance, South Africa[J]. Lancet, 2022, 400: 269-271. doi:  10.1016/S0140-6736(22)01190-4
    [46] Lewnard JA, Hong VX, Patel MM, et al. Clinical outcomes associated with SARS-CoV-2 Omicron (B. 1.1.529) variant and BA. 1/BA. 1.1 or BA. 2 subvariant infection in Southern California[J]. Nat Med, 2022, 28: 1933-1943. doi:  10.1038/s41591-022-01887-z
    [47] Davies MA, Morden E, Rosseau P, et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA. 4 and BA. 5 compared with previous waves in the Western Cape Province, South Africa[J]. Int J Infect Dis, 2022, 127: 63-68.
    [48] Hui KPY, Ho JCW, Cheung M, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo[J]. Nature, 2022, 603: 715-720. doi:  10.1038/s41586-022-04479-6
    [49] Halfmann PJ, Iida S, Iwatsuki-Horimoto K, et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters[J]. Nature, 2022, 603: 687-692. doi:  10.1038/s41586-022-04441-6
    [50] Christie B. COVID-19: Early studies give hope omicron is milder than other variants[J]. BMJ, 2021, 375: n3144.
    [51] Zhou H, Tada T, Dcosta BM, et al. Neutralization of SARS-CoV-2 Omicron BA. 2 by Therapeutic Monoclonal Antibodies[J]. bioRxiv[Preprint], 2022 Feb 24: 2022.02.15.480166.
    [52] Nutalai R, Zhou D, Tuekprakhon A, et al. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees[J]. Cell, 2022, 185: 2116-2131. e18. doi:  10.1016/j.cell.2022.05.014
    [53] Kurhade C, Zou J, Xia H, et al. Neutralization of Omicron BA. 1, BA. 2, and BA. 3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine[J]. Nat Commun, 2022, 13: 3602. doi:  10.1038/s41467-022-30681-1
    [54] Ai J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost[J]. Emerg Microbes Infect, 2022, 11: 337-343. doi:  10.1080/22221751.2021.2022440
    [55] Dupont L, Snell LB, Graham C, et al. Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern[J]. Nat Microbiol, 2021, 6: 1433-1442. doi:  10.1038/s41564-021-00974-0
    [56] Zou J, Kurhade C, Xia H, et al. Cross-neutralization of Omicron BA. 1 against BA. 2 and BA. 3 SARS-CoV-2[J]. Nat Commun, 2022, 13: 2956. doi:  10.1038/s41467-022-30580-5
    [57] Hachmann NP, Miller J, Collier AY, et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA. 2.12.1, BA. 4, and BA. 5[J]. N Engl J Med, 2022, 387: 86-88. doi:  10.1056/NEJMc2206576
    [58] Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19[J]. Nat Rev Immunol, 2021, 21: 382-393. doi:  10.1038/s41577-021-00542-x
    [59] Ohashi H, Hishiki T, Akazawa D, et al. Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA. 1 and BA. 2[J]. Antiviral Res, 2022, 205: 105372. doi:  10.1016/j.antiviral.2022.105372
    [60] Imai M, Ito M, Kiso M, et al. Efficacy of Antiviral Agents against Omicron Subvariants BQ. 1.1 and XBB[J]. N Engl J Med, 2023, 388: 89-91.
    [61] Davis-Gardner ME, Lai L, Wali B, et al. Neutralization against BA. 2.75.2, BQ. 1.1, and XBB from mRNA Bivalent Booster[J]. N Engl J Med, 2023, 388: 183-185. doi:  10.1056/NEJMc2214293
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1194) PDF downloads(82) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return